The use of therapeutic peptides to target and to kill cancer cells.

Peptide therapeutics is a promising field for emerging anti-cancer agents. Benefits include the ease and rapid synthesis of peptides and capacity for modifications. An existing and vast knowledge base of protein structure and function can be exploited for novel peptide design. Current research focuses on developing peptides that can (1) serve as tumor targeting moieties and (2) permeabilize membranes with cytotoxic consequences. A survey of recent findings reveals significant trends. Amphiphilic peptides with clusters of hydrophobic and cationic residues are features of anti-microbial peptides that confer the ability to eradicate microbes and show considerable anti-cancer toxicity. Peptides that assemble and form pores can disrupt cell or organelle membranes and cause apoptotic or necrotic death. Cell permeable and tumor-homing peptides can carry biologically active cargo to tumors or tumor vasculature. The challenge lies in developing the clinical application of therapeutic peptides. Improving delivery to tumors, minimizing non-specific toxic effects and discerning pharmacokinetic properties are high among the needs to produce a powerful therapeutic peptide for cancer treatment.

[1]  S. Korsmeyer,et al.  BAX-dependent transport of cytochrome c reconstituted in pure liposomes , 2000, Nature Cell Biology.

[2]  G. Diamond,et al.  Isolation and Characterization of Pleurocidin, an Antimicrobial Peptide in the Skin Secretions of Winter Flounder* , 1997, The Journal of Biological Chemistry.

[3]  J. Mai,et al.  A proapoptotic peptide for the treatment of solid tumors. , 2001, Cancer research.

[4]  Jingqiu Cheng,et al.  Enhancement of cytotoxicity of antimicrobial peptide magainin II in tumor cells by bombesin-targeted delivery , 2011, Acta Pharmacologica Sinica.

[5]  M. Stöckle,et al.  Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells , 2008, BMC urology.

[6]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[7]  O. Olopade,et al.  Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. , 1997, The cancer journal from Scientific American.

[8]  C. Bucana,et al.  Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. , 1991, Cancer research.

[9]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[10]  D. Engelman,et al.  Targeting acidic diseased tissue: New technology based on use of the pH (Low) Insertion Peptide (pHLIP). , 2009, Chimica oggi.

[11]  D. Noonan,et al.  Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth , 2010, Oncogene.

[12]  P. Colman,et al.  BCL-2 family antagonists for cancer therapy , 2008, Nature Reviews Drug Discovery.

[13]  G. Gillet,et al.  Bax-derived membrane-active peptides act as potent and direct inducers of apoptosis in cancer cells , 2011, Journal of Cell Science.

[14]  S. Batra,et al.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells , 2010, Oncogene.

[15]  Orlando L. Sánchez-Muñoz,et al.  A lipocentric view of peptide-induced pores , 2011, European Biophysics Journal.

[16]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[17]  Y. Shai,et al.  Host defense peptides as new weapons in cancer treatment , 2005, Cellular and Molecular Life Sciences CMLS.

[18]  Derek W. Yecies,et al.  Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. , 2010, Blood.

[19]  Erkki Ruoslahti,et al.  Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.

[20]  M. Bibby,et al.  Preliminary experimental anticancer activity of cecropins. , 1994, Peptide research.

[21]  E. Solary,et al.  Human defensins as cancer biomarkers and antitumour molecules. , 2009, Journal of proteomics.

[22]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[23]  A. M. van der Bliek,et al.  Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. , 1990, Cancer research.

[24]  S. Chan,et al.  Effects of the anti-bacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer cells. , 1997, Biochimica et biophysica acta.

[25]  D. Andrews,et al.  Still embedded together binding to membranes regulates Bcl-2 protein interactions , 2010, Oncogene.

[26]  Nico Tjandra,et al.  Structure of Bax Coregulation of Dimer Formation and Intracellular Localization , 2000, Cell.

[27]  I. Mingarro,et al.  Peptides corresponding to helices 5 and 6 of Bax can independently form large lipid pores , 2006, The FEBS journal.

[28]  London Wc,et al.  De Novo Antimicrobial Peptides with Low Mammalian Cell Toxicity , 1996 .

[29]  D. Hoskin,et al.  Studies on anticancer activities of antimicrobial peptides. , 2008, Biochimica et biophysica acta.

[30]  T. Kaku,et al.  Effect of defensin peptides on eukaryotic cells: primary epithelial cells, fibroblasts and squamous cell carcinoma cell lines. , 2004, Journal of dermatological science.

[31]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[32]  Hao Xiong,et al.  Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. García-Sáez,et al.  Role of membrane lipids for the activity of pore forming peptides and proteins. , 2010, Advances in experimental medicine and biology.

[34]  D. Engelman,et al.  Energetics of peptide (pHLIP) binding to and folding across a lipid bilayer membrane , 2008, Proceedings of the National Academy of Sciences.

[35]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[36]  J. Barker,et al.  Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[37]  H. Kosmehl,et al.  Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. , 2001, Cancer research.

[38]  K. Yoshida,et al.  Interaction of pleurocidin and its analogs with phospholipid membrane and their antibacterial activity. , 2001, The journal of peptide research : official journal of the American Peptide Society.

[39]  Fionnuala T Lundy,et al.  The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) in vitro. , 2006, Oral oncology.

[40]  M. Higashiyama,et al.  High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. , 1995, Anticancer research.

[41]  D. Ribatti,et al.  Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. , 2003, Cancer research.

[42]  Maurice Green,et al.  Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein , 1988, Cell.

[43]  S. Qian,et al.  Structure of transmembrane pore induced by Bax-derived peptide: Evidence for lipidic pores , 2008, Proceedings of the National Academy of Sciences.

[44]  Ø. Rekdal,et al.  BMC Cancer BioMed Central Study protocol , 2008 .

[45]  Xuan Huang,et al.  RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells , 2011, International journal of nanomedicine.

[46]  A. Patrzykat,et al.  Novel Antimicrobial Peptides Derived from Flatfish Genes , 2003, Antimicrobial Agents and Chemotherapy.

[47]  T. Ganz,et al.  Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[48]  P. Cao,et al.  Expression and Functional Characterization of Tumor-Targeted Fusion Protein Composed of NGR Peptide and 15-kDa Actin Fragment , 2010, Applied biochemistry and biotechnology.

[49]  Chiara Brignole,et al.  Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. , 2006, Cancer research.

[50]  W. Mackinnon,et al.  Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts , 1988, International journal of cancer.

[51]  M. Sentjurc,et al.  Cell membrane fluidity and prognosis of lung cancer. , 2002, The Annals of thoracic surgery.

[52]  E. Ruoslahti,et al.  Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma , 2011, Proceedings of the National Academy of Sciences.

[53]  E. Snyder,et al.  Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide , 2004, PLoS biology.

[54]  H. Hammes,et al.  Regulation of neovascularization by human neutrophil peptides (α‐defensins): a link between inflammation and angiogenesis , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  Vladimir P Torchilin,et al.  Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. , 2008, Advanced drug delivery reviews.

[56]  W. Wilson,et al.  Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. , 2010, The Lancet. Oncology.

[57]  V. Torchilin,et al.  Intracellular delivery of nanoparticles with CPPs. , 2011, Methods in molecular biology.

[58]  Hideyoshi Harashima,et al.  Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. , 2010, International journal of pharmaceutics.

[59]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[60]  Susan Chang,et al.  Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery , 2011, Journal of Neuro-Oncology.

[61]  J. Schneider,et al.  Materials from peptide assembly: towards the treatment of cancer and transmittable disease , 2011, Current Opinion in Chemical Biology.

[62]  N. Fujii,et al.  Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. , 1997, Biochimica et biophysica acta.

[63]  R. Gambrell,et al.  Peptide targeting of platinum anti-cancer drugs. , 2009, Bioconjugate chemistry.

[64]  E. Yavin,et al.  Multiple Triphenylphosphonium Cations as a Platform for the Delivery of a Pro-Apoptotic Peptide , 2011, Pharmaceutical Research.

[65]  D. Shin,et al.  The cell penetrating ability of the proapoptotic peptide, KLAKLAKKLAKLAK fused to the N-terminal protein transduction domain of translationally controlled tumor protein, MIIYRDLISH. , 2011, Biomaterials.

[66]  M. Yarmush,et al.  Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells. , 2007, Cancer research.

[67]  Erkki Ruoslahti,et al.  Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.

[68]  Young-Suk Choi,et al.  Cell‐penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy , 2011, International journal of cancer.

[69]  D. Hoskin,et al.  Pleurocidin-family cationic antimicrobial peptides are cytolytic for breast carcinoma cells and prevent growth of tumor xenografts , 2011, Breast Cancer Research.

[70]  Jijin Gu,et al.  Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors. , 2011, Biomaterials.

[71]  S. Lowe,et al.  Genetic analysis of chemoresistance in primary murine lymphomas , 2000, Nature Medicine.

[72]  J. Gera,et al.  Human neutrophil peptide defensins induce single strand DNA breaks in target cells. , 1991, Cellular immunology.

[73]  D. Engelman,et al.  pH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents , 2010, Molecular membrane biology.

[74]  P. Bulet,et al.  Antiviral and antitumor peptides from insects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[75]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[76]  M. Herlyn,et al.  Experimental local therapy of human melanoma with lytic magainin peptides , 1995, International journal of cancer.

[77]  T. Ganz,et al.  In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. , 1986, Blood.

[78]  M. Asslaber,et al.  In search of a novel target — Phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy , 2011, Biochimica et biophysica acta.

[79]  A. I. Arunkumar,et al.  Crumpled structure of the custom hydrophobic lytic peptide cecropin B3. , 2001, European journal of biochemistry.

[80]  A. Roberts,et al.  Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies , 2011, Pathology.

[81]  Carl O. Pabo,et al.  Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.

[82]  John Calvin Reed,et al.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. , 1993, Blood.

[83]  F. D. De Braud,et al.  Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma , 2010, British Journal of Cancer.

[84]  Hueih Min Chen,et al.  The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. , 2002, Anticancer research.

[85]  S. Schwarze,et al.  In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.

[86]  M. Rhee,et al.  Mechanism of Uptake of C105Y, a Novel Cell-penetrating Peptide* , 2006, Journal of Biological Chemistry.

[87]  M. Zasloff,et al.  Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor , 1987 .

[88]  E. Ruoslahti,et al.  Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[89]  Zhe Wang,et al.  APD: the Antimicrobial Peptide Database , 2004, Nucleic Acids Res..

[90]  A. Petros,et al.  Solution structure of the antiapoptotic protein bcl-2 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[91]  G. Sherbet Membrane fluidity and cancer metastasis. , 1989, Experimental cell biology.

[92]  M. Zasloff,et al.  Anticancer efficacy of Magainin2 and analogue peptides. , 1993, Cancer research.

[93]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[94]  D. Engelman,et al.  Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo , 2007, Proceedings of the National Academy of Sciences.

[95]  Junying Yuan,et al.  Solution Structure of BID, an Intracellular Amplifier of Apoptotic Signaling , 1999, Cell.

[96]  D. Hughes,et al.  The Apoptotic Protein tBid Promotes Leakage by Altering Membrane Curvature* , 2002, The Journal of Biological Chemistry.

[97]  H. Vogel,et al.  Relative Spatial Positions of Tryptophan and Cationic Residues in Helical Membrane-active Peptides Determine Their Cytotoxicity* , 2011, The Journal of Biological Chemistry.

[98]  D. Andrews,et al.  BH3-only proteins: Orchestrators of apoptosis. , 2011, Biochimica et biophysica acta.

[99]  D. Engelman,et al.  Spontaneous, pH-dependent membrane insertion of a transbilayer alpha-helix. , 1997, Biochemistry.

[100]  M. Mccarty,et al.  Manipulating tumor acidification as a cancer treatment strategy. , 2010, Alternative medicine review : a journal of clinical therapeutic.

[101]  U. Settmacher,et al.  Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. , 2005, Gastroenterology.

[102]  Friedrich Paulsen,et al.  Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines. , 2006, European urology.

[103]  D. Green,et al.  Minimal BH3 Peptides Promote Cell Death by Antagonizing Anti-apoptotic Proteins* , 2003, Journal of Biological Chemistry.

[104]  H. Dosaka-akita,et al.  Bcl-2 Expression in Non-Small Cell Lung Cancers: Higher Frequency of Expression in Squamous Cell Carcinomas with Earlier pT Status , 1999, Oncology.

[105]  V. Torchilin,et al.  “Smart” Drug Carriers: PEGylated TATp-Modified pH-Sensitive Liposomes , 2007, Journal of liposome research.

[106]  R K Jain,et al.  Transport of molecules, particles, and cells in solid tumors. , 1999, Annual review of biomedical engineering.

[107]  M. Tsao,et al.  Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma , 2008, Modern Pathology.

[108]  Michael J. McGuire,et al.  A Peptide Selected by Biopanning Identifies the Integrin αvβ6 as a Prognostic Biomarker for Nonsmall Cell Lung Cancer , 2007 .

[109]  T. Mikkelsen,et al.  Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[111]  Sabrina Riedl,et al.  Membrane-active host defense peptides – Challenges and perspectives for the development of novel anticancer drugs , 2011, Chemistry and physics of lipids.

[112]  Eun Seong Lee,et al.  A novel pH-responsive polysaccharidic ionic complex for proapoptotic D-(KLAKLAK)2 peptide delivery. , 2011, Chemical communications.

[113]  T. Hambley,et al.  Is anticancer drug development heading in the right direction? , 2009, Cancer research.

[114]  Soon-ja Kim,et al.  Effects of the synthetic coprisin analog peptide, CopA3 in pathogenic microorganisms and mammalian cancer cells. , 2012, Journal of microbiology and biotechnology.

[115]  V. Torchilin,et al.  "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. , 2006, Bioconjugate chemistry.

[116]  Joy Joseph,et al.  Doxorubicin-induced apoptosis: Implications in cardiotoxicity , 2002, Molecular and Cellular Biochemistry.

[117]  I. Mingarro,et al.  Peptides derived from apoptotic Bax and Bid reproduce the poration activity of the parent full-length proteins. , 2005, Biophysical journal.

[118]  S. Korsmeyer,et al.  A stapled BID BH3 helix directly binds and activates BAX. , 2006, Molecular cell.

[119]  W. Arap,et al.  The neovasculature homing motif NGR: more than meets the eye. , 2008, Blood.

[120]  R. Weissleder,et al.  A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity , 2006, Molecular Cancer Therapeutics.

[121]  R. Meadows,et al.  X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death , 1996, Nature.

[122]  A. Schroit,et al.  Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. , 1997, Blood.

[123]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[124]  P. Comfurius,et al.  Regulatory Mechanisms in Maintenance and Modulation of Transmembrane Lipid Asymmetry: Pathophysiological Implications , 1996, Lupus.

[125]  Vladimir P Torchilin,et al.  Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[126]  Jason L. Townson,et al.  Ineffectiveness of Doxorubicin Treatment on Solitary Dormant Mammary Carcinoma Cells or Late-developing Metastases , 2003, Breast Cancer Research and Treatment.